Lataa...
Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
Pembrolizumab is an immune checkpoint inhibitor (ICI) that targets the programmed cell death (PD)-1 receptor. It significantly increases the overall survival in patients with locally advanced or metastatic urothelial cancer. However, its administration may induce serious immune-related adverse effec...
Tallennettuna:
| Julkaisussa: | eNeurologicalSci |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082602/ https://ncbi.nlm.nih.gov/pubmed/32211521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ensci.2020.100236 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|